• Je něco špatně v tomto záznamu ?

Molnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic

P. Dlouhý, C. Mucha, L. Mokrá, M. Kuhn, L. Hrdlickova, U. Arnet, Y. Whiteside

. 2024 ; 13 (8) : . [pub] 20240416

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24012992

Background/Objectives: Molnupiravir (MOV), an oral antiviral COVID-19 treatment, was introduced in the Czech Republic in December 2021 for COVID-19 patients at a high risk of progression to severe disease requiring hospitalization. In this observational, retrospective study, we aimed to describe the characteristics and healthcare resource utilization in non-hospitalized, adult COVID-19 patients prescribed MOV in the Czech Republic between 1 January and 30 April 2022. Methods: A total of 621 patients were included and followed up with for 28 days. Results: The median age was 68.0 (20-99) years, 77.8% were overweight or obese, 14.1% smoked, and 85.7% were vaccinated. The overall cumulative incidence (95% CI) of all-cause hospitalization was 0.71 (0.37; 1.24) per 1000 person years or 1.9%, with similar rates across sexes, age groups, BMI category, multimorbidity category, polypharmacy category, and COVID-19 vaccination status. Among patients reported hospitalized, oxygen-based resources were not observed, and no deaths occurred. Conclusions: These data describe the characteristics and healthcare resource utilization in Czech MOV-treated patients whose clinical characteristics may put them at increased risk of severe disease.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24012992
003      
CZ-PrNML
005      
20240726151458.0
007      
ta
008      
240723s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/jcm13082303 $2 doi
035    __
$a (PubMed)38673576
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Dlouhý, Pavel $u Infectious Disease Department, Krajská Zdravotní, a.s., 400 11 Ústí nad Labem, Czech Republic
245    10
$a Molnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic / $c P. Dlouhý, C. Mucha, L. Mokrá, M. Kuhn, L. Hrdlickova, U. Arnet, Y. Whiteside
520    9_
$a Background/Objectives: Molnupiravir (MOV), an oral antiviral COVID-19 treatment, was introduced in the Czech Republic in December 2021 for COVID-19 patients at a high risk of progression to severe disease requiring hospitalization. In this observational, retrospective study, we aimed to describe the characteristics and healthcare resource utilization in non-hospitalized, adult COVID-19 patients prescribed MOV in the Czech Republic between 1 January and 30 April 2022. Methods: A total of 621 patients were included and followed up with for 28 days. Results: The median age was 68.0 (20-99) years, 77.8% were overweight or obese, 14.1% smoked, and 85.7% were vaccinated. The overall cumulative incidence (95% CI) of all-cause hospitalization was 0.71 (0.37; 1.24) per 1000 person years or 1.9%, with similar rates across sexes, age groups, BMI category, multimorbidity category, polypharmacy category, and COVID-19 vaccination status. Among patients reported hospitalized, oxygen-based resources were not observed, and no deaths occurred. Conclusions: These data describe the characteristics and healthcare resource utilization in Czech MOV-treated patients whose clinical characteristics may put them at increased risk of severe disease.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mucha, Cyril $u Institute of General Practice, First Faculty of Medicine, Charles University, 110 00 Prague, Czech Republic
700    1_
$a Mokrá, Lenka $u Institute of Biostatistics and Analyses, Ltd., 625 00 Brno, Czech Republic
700    1_
$a Kuhn, Matyáš $u Institute of Biostatistics and Analyses, Ltd., 625 00 Brno, Czech Republic
700    1_
$a Hrdlickova, Lenka $u MSD Czech Republic, 150 00 Prague, Czech Republic
700    1_
$a Arnet, Urs $u Center for Observational and Real-World Evidence (CORE), MSD Innovation & Development GmbH, 8058 Zürich, Switzerland $1 https://orcid.org/000900079592620X
700    1_
$a Whiteside, Yohance $u Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Rahway, NJ 07065, USA $1 https://orcid.org/0000000278283018
773    0_
$w MED00195462 $t Journal of clinical medicine $x 2077-0383 $g Roč. 13, č. 8 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38673576 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240726151451 $b ABA008
999    __
$a ok $b bmc $g 2125555 $s 1224855
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 13 $c 8 $e 20240416 $i 2077-0383 $m Journal of clinical medicine $n J Clin Med $x MED00195462
LZP    __
$a Pubmed-20240723

Najít záznam

Citační ukazatele

Možnosti archivace